Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance
- PMID: 8553567
- DOI: 10.1006/viro.1995.0076
Isolation of cytotoxic T lymphocytes from healthy seropositive individuals specific for peptide epitopes from Epstein-Barr virus nuclear antigen 1: implications for viral persistence and tumor surveillance
Abstract
The question of whether Epstein-Barr nuclear antigen 1 (EBNA1) includes cytotoxic T lymphocyte (CTL) epitopes has generated considerable scientific interest, primarily due to its important implications for the overall biology of Epstein-Barr virus (EBV). Earlier studies have suggested that EBV-associated malignancies that express only EBNA1 escape virus-specific immune surveillance since this antigen is not a target for CTL recognition. In the present report we have used a modified protocol to demonstrate that EBNA1 includes sequences which can be recognized by both polyclonal and clonal CTLs. CD4+ CTL clones were isolated from a healthy, seropositive donor that recognized the peptide epitope TSLYNLRRGTALA from EBNA1 in association with HLA DR1. Interestingly, these CTLs are unable to lyse EBV-infected B cells suggesting that EBNA1 may not be endogenously processed and/or presented to the host CTL response. Despite recent suggestions that glycine-alanine repeat sequences within EBNA1 can inhibit endogenous processing, target cells infected with recombinant vaccinia vectors encoding truncated EBNA1 proteins, without these repeat sequences, were not recognized by this CTL clone. Thus it seems that the presence of glycine-alanine repeats is not responsible for inhibiting the processing of the class II-restricted epitope defined in this study. These results substantiate the view that EBV-infected normal and malignant cells, where viral gene expression is limited to EBNA1, can resist CTL-mediated immune surveillance in vivo.
Similar articles
-
Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.Eur J Immunol. 1998 Feb;28(2):451-8. doi: 10.1002/(SICI)1521-4141(199802)28:02<451::AID-IMMU451>3.0.CO;2-U. Eur J Immunol. 1998. PMID: 9521052
-
Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1.Nature. 1995 Jun 22;375(6533):685-8. doi: 10.1038/375685a0. Nature. 1995. PMID: 7540727
-
Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.J Exp Med. 1992 Jul 1;176(1):169-76. doi: 10.1084/jem.176.1.169. J Exp Med. 1992. PMID: 1377222 Free PMC article.
-
Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection.Annu Rev Immunol. 1997;15:405-31. doi: 10.1146/annurev.immunol.15.1.405. Annu Rev Immunol. 1997. PMID: 9143694 Review.
-
T cell recognition of Epstein-Barr virus associated lymphomas.Cancer Surv. 1992;13:53-80. Cancer Surv. 1992. PMID: 1330300 Review.
Cited by
-
Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity.J Virol. 2005 May;79(9):5477-88. doi: 10.1128/JVI.79.9.5477-5488.2005. J Virol. 2005. PMID: 15827162 Free PMC article.
-
Nuclear location of an endogenously expressed antigen, EBNA1, restricts access to macroautophagy and the range of CD4 epitope display.Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):2165-70. doi: 10.1073/pnas.0909448107. Epub 2010 Jan 19. Proc Natl Acad Sci U S A. 2010. PMID: 20133861 Free PMC article.
-
Type 2 cytokines predominate in the human CD4(+) T-lymphocyte response to Epstein-Barr virus nuclear antigen 1.J Virol. 2000 Aug;74(15):6748-59. doi: 10.1128/jvi.74.15.6748-6759.2000. J Virol. 2000. PMID: 10888613 Free PMC article.
-
CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.J Virol. 2001 Apr;75(8):3740-52. doi: 10.1128/JVI.75.8.3740-3752.2001. J Virol. 2001. PMID: 11264363 Free PMC article.
-
Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.Springer Semin Immunopathol. 1998;20(3-4):455-91. doi: 10.1007/BF00838055. Springer Semin Immunopathol. 1998. PMID: 9870257 Review. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials